MYCN overexpression has been reported in haematologic malignancies, such as lymphoma,27 chronic lymphocytic leukaemia (CLL) 28 and paediatric T‐ALL,29 and it is considered a well‐established marker of a poor prognosis in these diseases. The gene discussed is MYCN; the disease is lymphoma.